NEW YORK (GenomeWeb) – HTG Molecular Diagnostics said today that it has signed a research agreement with Spain's Instituto Valenciano de Oncología (IVO) to develop and validate a breast cancer recurrence risk score using the company's technology.
Under the terms of the deal, the partners will use HTG's EdgeSeq Oncology biomarker panel to develop a breast cancer recurrence risk score based on genes differentially expressed in patients with low and high risk of recurrence. Additional terms were not disclosed.
"The goal of this research collaboration is to develop a breast cancer recurrence score, based on HTG's technology, that is capable of using a single, formalin-fixed, paraffin-embedded (FFPE) tissue section that can be deployable for use by IVO and its affiliates for testing of breast cancer patients in Spain," Jose Antonio Lopez-Guerrero, head of the laboratory of molecular biology at IVO, said in a statement.
"We believe our HTG EdgeSeq chemistry is well suited for the initial project because it will allow IVO to develop their training set using a single, FFPE tissue section from each previously assessed case," HTG President and CEO T.J. Johnson added.